RESUMO
Hepatitis C virus (HCV) infection is a major public health problem in the European Union (EU). An estimated 5.6 million Europeans are chronically infected with a wide range of variation in prevalence across European Union countries. Although HCV continues to spread as a largely "silent pandemic," its elimination is made possible through the availability of the new antiviral drugs and the implementation of prevention practices. On 17 February 2016, the Hepatitis B & C Public Policy Association held the first EU HCV Policy Summit in Brussels. This summit was an historic event as it was the first high-level conference focusing on the elimination of HCV at the European Union level. The meeting brought together the main stakeholders in the field of HCV: clinicians, patient advocacy groups, representatives of key institutions and regional bodies from across European Union; it served as a platform for one of the most significant disease elimination campaigns in Europe and culminated in the presentation of the HCV Elimination Manifesto, calling for the elimination of HCV in Europe by 2030. The launch of the Elimination Manifesto provides a starting point for action in order to make HCV and its elimination in Europe an explicit public health priority, to ensure that patients, civil society groups and other relevant stakeholders will be directly involved in developing and implementing HCV elimination strategies, to pay particular attention to the links between hepatitis C and social marginalization and to introduce a European Hepatitis Awareness Week.
Assuntos
Antivirais/uso terapêutico , Erradicação de Doenças/organização & administração , Hepacivirus/fisiologia , Hepatite C/prevenção & controle , Erradicação de Doenças/economia , Monitoramento Epidemiológico , Europa (Continente)/epidemiologia , União Europeia , Hepatite C/epidemiologia , Hepatite C/virologia , Humanos , PrevalênciaRESUMO
We compared the cost-effectiveness of various noninvasive tests (NITs) in patients with chronic hepatitis B and elevated transaminases and/or viral load who would normally undergo liver biopsy to inform treatment decisions. We searched various databases until April 2012. We conducted a systematic review and meta-analysis to calculate the diagnostic accuracy of various NITs using a bivariate random-effects model. We constructed a probabilistic decision analytical model to estimate health care costs and outcomes quality-adjusted-life-years (QALYs) using data from the meta-analysis, literature, and national UK data. We compared the cost-effectiveness of four decision-making strategies: testing with NITs and treating patients with fibrosis stage ≥F2, testing with liver biopsy and treating patients with ≥F2, treat none (watchful waiting) and treat all irrespective of fibrosis. Treating all patients without prior fibrosis assessment had an incremental cost-effectiveness ratio (ICER) of £28,137 per additional QALY gained for HBeAg-negative patients. For HBeAg-positive patients, using Fibroscan was the most cost-effective option with an ICER of £23,345. The base case results remained robust in the majority of sensitivity analyses, but were sensitive to changes in the ≥ F2 prevalence and the benefit of treatment in patients with F0-F1. For HBeAg-negative patients, strategies excluding NITs were the most cost-effective: treating all patients regardless of fibrosis level if the high cost-effectiveness threshold of £30,000 is accepted; watchful waiting if not. For HBeAg-positive patients, using Fibroscan to identify and treat those with ≥F2 was the most cost-effective option.
Assuntos
Análise Custo-Benefício , Testes Diagnósticos de Rotina/economia , Custos de Cuidados de Saúde , Cirrose Hepática/diagnóstico , Cirrose Hepática/economia , Antivirais/uso terapêutico , Erros de Diagnóstico/economia , Erros de Diagnóstico/estatística & dados numéricos , Antígenos E da Hepatite B/sangue , Hepatite B Crônica , Humanos , Cirrose Hepática/tratamento farmacológico , Anos de Vida Ajustados por Qualidade de Vida , Reino Unido , Carga ViralRESUMO
Histological severity is often mandatory for the management of HBeAg-negative chronic HBV patients. We evaluated the performance of transient elastography (TE) in this setting. We included 357 untreated HBeAg-negative patients with ≥ 1 reliable liver stiffness measurement (LSM-kPa) by TE: 182 inactive carriers with HBV-DNA < 2000 (n = 139) or 2000-19 999 IU/mL (n = 43) and 175 patients with chronic hepatitis B (CHB). In carriers, HBV-DNA > 2000 and/or LSM > 6.5 were considered as biopsy indications. LSMs did not differ between carriers with low and high viremia, but were lower in carriers than in patients with CHB (5.8 ± 1.7 vs 9.0 ± 5.6, P < 0.001) offering moderate differentiation between these two groups (AUROC: 0.705). LSMs did not change significantly in carriers after 16 (12-24) months. In carriers with a liver biopsy, Ishak's staging scores were similar between cased with low and high viremia but higher in cases with LSM > 6.5 than ≤ 6.5 kPa. Moderate fibrosis (stages: 2-3) was detected in 0/10 carriers with only HBV-DNA > 2000 IU/mL, 2/10 (20%) carriers with only LSM > 6.5 and 5/10 (50%) carriers with both HBV-DNA > 2000 and LSM > 6.5 (P = 0.009). In patients with CHB, LSMs correlated significantly with grading and staging scores and offered excellent accuracy for ≥ moderate, ≥ severe fibrosis or cirrhosis (AUROC ≥ 0.919-0.950). TE can be helpful for the noninvasive assessment of HBeAg-negative chronic HBV patients. In conclusion, LSMs offer excellent accuracy for fibrosis severity in HBeAg-negative patients with CHB and can identify carriers with high risk of moderate fibrosis, which may be present in up to 35% of carriers with LSM > 6.5 kPa and 50% of carriers with LSM > 6.5 kPa and HBV-DNA > 2000 IU/mL.
Assuntos
Técnicas de Imagem por Elasticidade/métodos , Antígenos E da Hepatite B/sangue , Hepatite B Crônica/complicações , Cirrose Hepática/diagnóstico , Adulto , Idoso , Feminino , Hepatite B Crônica/virologia , Humanos , Cirrose Hepática/patologia , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de DoençaRESUMO
OBJECTIVES: To study the prevalence of gastrointestinal symptoms in the Greek urban general population, their associations with patient characteristics, and their effect on patients' daily activities. MATERIAL AND METHODS: The study included 700 adults from the Athens-Piraeus area selected by a 2-stage scheme based on the official maps of the Hellenic Statistic Service. Structured questionnaires were completed through personal interviews. Dyspepsia, gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) were diagnosed according to widely accepted definitions. RESULTS: Of the 700 individuals, 53% reported > or = 1 gastrointestinal symptom during the past week and 55% during the past 6 months (dyspepsia: 48%, GERD: 38%, IBS: 21%). Only one disorder was diagnosed in 25% (dyspepsia: 18%, GERD: 7%), and > or = 2 disorders in 75% of symptomatic individuals. Dyspepsia or GERD was predominant in 7% and 16% and IBS in 28% and 19% of the patients with relevant symptoms during the past week and the past 6 months, respectively (p = 0.017). Substantial symptoms during the past 6 months were reported by 60% of the symptomatic individuals. Affected daily activities were reported by 22% of symptomatic and 5% of asymptomatic individuals (p < 0.001). CONCLUSIONS: Gastrointestinal symptoms are highly prevalent in the Greek urban general population and are substantial in the majority of symptomatic individuals. Dyspepsia and GERD are reported much more frequently than IBS symptoms, but there is a significant overlap between symptomatic diagnoses, while the predominant diagnosis may change over time. Gastrointestinal symptoms have a significant impact on patients' daily activities.
Assuntos
Dispepsia/epidemiologia , Gastroenteropatias/epidemiologia , Atividades Cotidianas , Adulto , Idoso , Efeitos Psicossociais da Doença , Feminino , Refluxo Gastroesofágico/epidemiologia , Grécia/epidemiologia , Humanos , Síndrome do Intestino Irritável/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , População UrbanaRESUMO
OBJECTIVES: To determine the severity of hepatic histological lesions in anti-HCV positive parenteral drug abusers and to correlate it with the level of ALT activity and HCV RNA determined by polymerase chain reaction (PCR). METHODS: Twenty-nine of the 62 anti-HCV-positive parenteral drug abusers who consecutively entered a Rehabilitation Center of Athens consented to liver biopsy and were prospectively and thoroughly followed up for a mean of 12.9 (range 6-33) months. Anti-HCV was detected by a second-generation enzyme immunoassay and confirmed by a second-generation recombinant immunoblot assay. Serum samples were tested for HCV RNA by nested PCR with primers from the highly conserved 5' untranslated region of the HCV genome. RESULTS: Liver biopsy revealed lesions compatible with chronic hepatitis in 26 (89.6%) and a normal liver in three (10.4%) of the 29 patients. In particular, 11 (37.9%) had minimal and 15 (57.1%) had mild chronic hepatitis; fibrosis was absent or mild in all cases. Histological grade and stage were significantly milder in patients with persistently normal ALT activity than in those with increased ALT activity. However, chronic hepatitis was observed in five (62.5%) of the eight patients with normal ALT levels. The presence of serum HCV RNA was not significantly correlated with the severity of histological lesions. HCV RNA was detected in 16 (57.1%) of the 28 cases tested. In particular, HCV RNA was detected in one (33.3%) of the three cases with normal liver and in three (37.5%) of the eight patients with normal ALT levels. CONCLUSIONS: Liver biopsy appears to be the method of choice for the accurate evaluation of anti-HCV positive parenteral drug abusers, irrespective of ALT activity and presence of serum HCV RNA. Chronic hepatitis is observed in the majority and the state of "healthy" carrier of HCV in the minority of this epidemiological setting.